The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC).

About tivozanib

Tivozanib is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor.

In the current clinical trial, 351 patients with advanced RCC were treated with either tivozanib or Nexavar (sorafenib) and directly compared.  The “TIV-3” trial included patients with RCC who have failed at least two prior regimens.

Overall the treatment was well tolerated and more than twice as many tivozanib treated patients responded to treated and these individuals survived without cancer progression an average of 5.6 months compared to 3.9 months for those treated with Nexavar.

The final survival analysis of TIV – 3 is expected in August 2019, and the drug manufacturer, AVEO said it intends to submit a New Drug Application to the U.S. Food and Drug Administration within the next six months. Tivozanib has been approved for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. In those markets, it is sold under the brand name of Fotivda.

Reference

https://www.biospace.com/article/aveo-s-rcc-drug-hits-the-mark-in-phase-iii-trial/

Copyright © 2018 CancerConnect. All Rights Reserved.